Lanadelumab for the prevention of attacks in hereditary angioedema

References

• Zuraw BL, Christiansen SC. HAE pathophysiology and underlying mechanisms. Clin Rev Allergy Immunol. 2016;51(2):216–229.
   PubMed Web of Science ®Google Scholar
• Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. 2008;359(10):1027–1036.
   PubMed Web of Science ®Google Scholar
• Bernstein JA. HAE update: epidemiology and burden of disease. Allergy Asthma Proc. 2013;34(1):3–6.
   PubMed Web of Science ®Google Scholar
• Longhurst H, Bygum A. The humanistic, societal, and pharmaco-economic burden of angioedema. Clin Rev Allergy Immunol. 2016;51(2):230–239.
   PubMed Web of Science ®Google Scholar
• Bygum A, Aygoren-Pursun E, Beusterien K, et al. Burden of illness in hereditary angioedema: a conceptual model. Acta Derm Venereol. 2015;95(6):706–710.
   PubMed Web of Science ®Google Scholar
• Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an international working group. Allergy. 2012;67(2):147–157.
   PubMed Web of Science ®Google Scholar
• Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. Allergy. 2018;73(8):1575–1596.
   PubMed Web of Science ®Google Scholar
• Perego F, Wu MA, Valerieva A, et al. Current and emerging biologics for the treatment of hereditary angioedema. Expert Opin Biol Ther. 2019;19(6):517–526.
   PubMed Web of Science ®Google Scholar
• Banerji A, Busse P, Shennak M, et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. N Engl J Med. 2017;376(8):717–728.
   PubMed Web of Science ®Google Scholar
• Chyung Y, Vince B, Iarrobino R, et al. A phase 1 study investigating DX-2930 in healthy subjects. Ann Allergy Asthma Immunol. 2014;113(4):460–466 e462.
   PubMed Web of Science ®Google Scholar
• Kenniston JA, Faucette RR, Martik D, et al. Inhibition of plasma kallikrein by a highly specific active site blocking antibody. J Biol Chem. 2014;289(34):23596–23608.
   PubMed Web of Science ®Google Scholar
• Levy JH, O’Donnell PS. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin Investig Drugs. 2006;15(9):1077–1090.
   PubMed Web of Science ®Google Scholar
• Schneider L, Lumry W, Vegh A, et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol. 2007;120(2):416–422.
   PubMed Web of Science ®Google Scholar
• Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010;363(6):523–531.
   PubMed Web of Science ®Google Scholar
• Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104(6):523–529.
   PubMed Web of Science ®Google Scholar
• Lumry WR, Bernstein JA, Li HH, et al. Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study. Allergy Asthma Proc. 2013;34(2):155–161.
   PubMed Web of Science ®Google Scholar
• Riedl MA. Critical appraisal of androgen use in hereditary angioedema: a systematic review. Ann Allergy Asthma Immunol. 2015;114(4):281–288 e287.
   PubMed Web of Science ®Google Scholar
• Bouillet L, Boccon-Gibod I, Launay D et al. Shortage in France of plasma derived C1-INH concentrates: state of play and consequences for patients. 11th C1-inhibitor Deficiency & Angioedema Workshop; Budapest, 23–26 May 2019, short communication.
   Google Scholar
• Riedl MA, Aygoren-Pursun E, Baker J, et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy. 2018;73(9):1871–1880.
   PubMed Web of Science ®Google Scholar
• Aygoren-Pursun E, Bygum A, Grivcheva-Panovska V, et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. N Engl J Med. 2018;379(4):352–362.
   PubMed Web of Science ®Google Scholar
• Stobiecki M, Aygören-Pürsün E, Andarawewa S et al. Clinical evaluation of pharmacokinetics, pharmacodynamics, safety, and efficacy dose-response of BCX7353 as an acute treatment for angioedema in patients with hereditary angioedema (HAE) 11th C1-inhibitor Deficiency & Angioedema Workshop; Budapest, 23–26 May 2019, short communication.
   Google Scholar
• Liu J, Qin J, Borodovsky A, et al. An investigational RNAi therapeutic targeting factor XII (ALN-F12) for the treatment of hereditary angioedema. RNA. 2019;25(2):255–263.
   PubMed Web of Science ®Google Scholar
• Maetzel A. KVD900, a new oral on-demand treatment of hereditary angioedema attacks achieves complete plasma kallikrein suppression: safety, tolerability, pharmacokinetic and pharmacodynamic results from a phase 1 first-in-human study. 11th C1-inhibitor Deficiency & Angioedema Workshop, 23–26 May 2019, short communication}{Ira Kalfus, O-26 Pharmacokinetics, safety, and potency of ATN-249, a novel oral plasma kallikrein inhibitor for hereditary angioedema. 11th C1-inhibitor Deficiency & Angioedema Workshop; Budapest, 23–26 May 2019, short communication.
   Google Scholar
• Lesage ASJ, Knolle J, Marceau F, et al. PHA-022121, the first-in-class orally active bradykinin receptor B2 antagonist for on-demand and prophylactic treatment of HAE. Allergy Asthma Clin Immunol. 2019;15(Suppl4):45. (O23).
   Google Scholar
• Hoet RM, Cohen EH, Kent RB, et al. Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat Biotechnol. 2005;23(3):344–348.
   PubMed Web of Science ®Google Scholar
• Marceau F, Bachelard H, Rivard GÉ, et al. Increased fibrinolysis-induced bradykinin formation in hereditary angioedema confirmed using stored plasma and biotechnological inhibitors. BMC Res Notes. 2019 May 27;12(1):291.
   PubMedGoogle Scholar
• Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108–2121.
   PubMed Web of Science ®Google Scholar
• Banerji A, Manning ME, Martinez-Saguer I, et al. Subgroup analyses from the phase 3 HELP study of lanadelumab for the prevention of hereditary angioedema attacks. J Allergy Clin Immunol. 2019;143(2):AB42.
   Web of Science ®Google Scholar
• Maurer M, Riedl MA, Bernstein JA et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks: findings from the HELP study. Abstract from EAACI Congress, Lisbon, 2019.
   Google Scholar
• Cicardi M, Maurer M, Longhurst HJ et al. Lanadelumab prophylaxis reduces breakthrough hereditary angioedema attacks and the need for rescue medication: findings from the phase 3 HELP study. Abstract from EAACI Congress, Lisbon, 2019.
   Google Scholar
• Riedl MA, Bernstein JA, Craig T, et al. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension. Clin Transl Allergy. 2017;7:36.
   Web of Science ®Google Scholar
• Riedl MA, Anderson JT, Cicardi M, et al. Efficacy of lanadelumab in hereditary angioedema patients switching from C1 inhibitor long-term prophylaxis: interim results from the HELP open-label extension study. J Allergy Clin Immunol. 2019 Feb;143(2):AB37.
   Web of Science ®Google Scholar
• Jacobs JS, Bernstein J, Davis-Lorton M, et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. J Allergy Clin Immunol. 2019;143(2):AB38.
   Web of Science ®Google Scholar
• Busse PJ, Tachdjian R, Martinez-Saguer I, et al. Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). J Allergy Clin Immunol. 2019 Feb;143(2):AB43.
   Web of Science ®Google Scholar
• Magerl M, Kiani-Alikhan S, Riedl MA et al. Efficacy and safety outcomes for switching to lanadelumab from prior long-term prophylaxis: findings from an interim analysis of the HELP OLE study. Abstract from EAACI Congress, Lisbon, 2019.
   Google Scholar
• Staubach P, Soteres D, Aygören-Pürsün E et al. Use of short-term prophylaxis during treatment with lanadelumab does not impact the risk of an attack: analysis of data from the HELP study and HELP OLE. Abstract from EAACI Congress, Lisbon, 2019.
   Google Scholar
• Yi W. The plasma contact system as a modulator of innate immunity. Curr Opin Hematol. 2018;25:389–394.
   PubMed Web of Science ®Google Scholar
• Bork K, Witzke G. Shortened activated partial thromboplastin time may help in diagnosing hereditary and acquired angioedema. Int Arch Allergy Immunol. 2016;170(2):101–107.
   PubMed Web of Science ®Google Scholar
• Schmaier A, Bauer KA, Cicardi M, et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. J Allergy Clin Immunol. 2019 Feb;143(2):AB41.
   Web of Science ®Google Scholar
• Sexton DJ, Brown NJ, Lumry WR, et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. J Allergy Clin Immunol. 2019 Feb;143(2):AB45.
   Web of Science ®Google Scholar
• Hathaway WE, Belhasen LP, Hathaway HS. Evidence for a new plasma thromboplastin factor. 1. Case report, coagulation studies, and physicochemical properties. Blood. 1965;26:521–532.
   PubMed Web of Science ®Google Scholar
• Girolami A, Scarparo P, Candeo N, et al. Congenital prekallikrein deficiency. Expert Rev Hematol. 2010;3(6):685–695.
   PubMed Web of Science ®Google Scholar
• Saito H. Studies on Fletcher trait and Fitzgerald trait. Thromb Haemost. 2010. DOI:10.1160/TH10-01-0058
   Web of Science ®Google Scholar
• Ratnoff OD. Some relationships among hemostasis, fibrinolytic phenomena, immunity, and the inflammatory response. Adv Immunol. 1969;10:145–227.
   PubMedGoogle Scholar